KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Long-Term Deferred Tax (2018 - 2019)

Novavax has reported Long-Term Deferred Tax over the past 2 years, most recently at $2.5 million for Q4 2019.

  • Quarterly results put Long-Term Deferred Tax at $2.5 million for Q4 2019, down 20.96% from a year ago — trailing twelve months through Dec 2019 was $2.5 million (down 20.96% YoY), and the annual figure for FY2019 was $2.5 million, down 20.96%.
  • Long-Term Deferred Tax for Q4 2019 was $2.5 million at Novavax, down from $3.2 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for NVAX hit a ceiling of $3.2 million in Q4 2018 and a floor of $2.5 million in Q4 2019.